Clinical trial NCT01888081: A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma
Official title: Phase I/II Trial of A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for the Treatment of Stage IV Melanoma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Melanoma
Lead sponsor: Angimmune LLC
Sponsor class: INDUSTRY
Collaborators: name: University of Louisville
First posted: 2013-06-27
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this trial is to study A-dmDT390-bisFv(UCHT1) in combination with ionizing irradiation for the treatment of stage IV melanoma, a disease that is essentially incurable with median overall survival periods that range from 8-16 months.

Detailed description: A-dmDT390-bisFv(UCHT1) (Resimmune™), an anti-T cell immunotoxin is currently being studied as a treatment for cutaneous T cell lymphoma and other CD3+ malignant diseases (FDA IND Number: 100712, Scott and White Protocol 071163). During the course of this study, data accumulated that Resimmune could be acting as an immunomodulator. This was based on the observation that four out of six partial responses converted to complete responses at times ranging between 6 and 24 months following the completion of the 4-day treatment protocol and no other treatment took place.

The purpose of this trial is to test the hypothesis that Resimmune can act as an immunomodulator of late stage metastatic melanoma when combined with palliative radiation to induce the priming of activated T cells with tumor antigens. The primary objective of this study is to determine the safety of combining Resimmune with palliative radiation therapy in patients with stage IV melanoma. A secondary objective is to document the tumor response and duration of response at irradiated and unirradiated sites (the abscopal effect). An additional secondary objective is to determine if T cell activation occurs following administration of A-dmDT390-bisFv(UCHT1) and local radiation to a metastatic lesion of melanoma.

Eligibility criteria: Inclusion Criteria:

* All patients must have histologically proven stage IV metastatic melanoma consisting of at least two lesions
* Patients must have a performance status of \< 2 on Eastern Cooperative Oncology Group scale (see Appendix).
* Patients must have bilirubin \< 1.5 mg/dL, transaminases \< 2.5 X ULN, albumin \> 3 gm/dL, creatinine \< 2.0 mg/dL, adequate pulmonary function by physical exam and pulse oximetry and adequate cardiac reserve (EF \> 50% normal). Patients must have a normal echocardiogram without any evidence of cardiac chamber hypertrophy, dilatation or hypokinesis.
* Patients must give written informed consent prior to registration.
* Females and males must be willing to use an approved form of birth control while on this study and for 2 weeks after completion.
* Patients of ages 18-80 are eligible provided they have stage IV melanoma and are negative for BRAF or have failed BRAF inhibitor treatment or if they have failed or are intolerant to other established therapy known to provide clinical benefit for their condition or if they have been adequately consented and agreed to forgo FDA approved clinically meaningful therapy

Exclusion Criteria:

* Inability to give informed consent because of psychiatric problems, or complicated medical problems.
* Serious concurrent medical problems, uncontrolled infections, or disseminated intravascular coagulopathy (DIC).
* Preexisting cardiovascular disease, the only exception being well controlled essential hypertension with a sitting blood pressure of \<155 systolic and \<90 diastolic without any evidence of structural heart disease or one episode of myocardial infarction \> 8 months ago. A past history of the any of the following are exclusions: congestive heart failure, atrial fibrillation, pulmonary hypertension, anticoagulant drug therapy, thromboembolic events, cardiomyopathy or a myocardial infarction within the past 8 months.
* Pregnant or nursing women will be excluded from study.
* History of congestive heart failure.
* History of cirrhosis of the liver

Primary outcomes:
measure: Immune-related overall response rate (irORR)
timeFrame: For up to 1 year post treatment or until disease progression
Secondary outcomes:
measure: Overall survival
timeFrame: every 3 months for up to 3 years
Other outcomes:
measure: Treatment Duration
timeFrame: 4 Days
Locations:
city: Louisville
country: United States
facility: James Graham Brown Cancer Center
state: Kentucky
Study officials:
affiliation: James Graham Brown Cancer Center, University of Louisville
name: Jason Chesney, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: